Deoxycholic Acid Obesity Drugs Market Report 2025

The deoxycholic acid obesity drug market size has grown rapidly in recent years. It will grow from $0.44 billion in 2024 to $0.5 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth during the historic period is attributed to the increasing preference for minimally invasive procedures, the rising number of aesthetic clinics and specialized treatment centers, growing consumer willingness to spend on cosmetic and obesity treatments, expanding clinical evidence supporting the efficacy and safety of deoxycholic acid injections, and increasing regulatory approvals and supportive policies in key markets.

The deoxycholic acid obesity drug market size is expected to see rapid growth in the next few years. It will grow to $0.85 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period is driven by the rising prevalence of obesity, growing demand for non-surgical fat reduction treatments, increasing awareness of body aesthetics and cosmetic procedures, higher investment in research and development for new deoxycholic acid formulations, and expanding availability of high-purity and combination therapy products. Key trends in the forecast period include the development of combination therapies, innovations in medical technology and treatment protocols, advancements in formulation technologies, integration of digital tools and artificial intelligence for treatment planning, and improvements in injection lipolysis formulations.

The increasing obesity rates are expected to drive the growth of the deoxycholic acid obesity drug market in the coming years. Obesity rates refer to the proportion of individuals in a population who are classified as overweight or obese based on their body mass index. The rise in obesity is largely influenced by unhealthy dietary patterns, including high consumption of processed foods and sugary beverages, which contribute to excessive calorie intake and fat accumulation in the body. Deoxycholic acid obesity drugs aid in addressing this issue by breaking down and eliminating fat cells, which leads to targeted fat reduction and improved body contour. For example, in September 2023, the Centers for Disease Control and Prevention, a government agency based in the United States, reported that in 2022, twenty-two states had adult obesity rates of thirty-five percent or higher, compared to nineteen states in 2021. As a result, the rising obesity rates are contributing to the growth of the deoxycholic acid obesity drug market.

The increasing demand for non-surgical body contouring solutions is expected to support the growth of the deoxycholic acid obesity drug market in the years ahead. Non-surgical body contouring involves treatments that are either non-invasive or minimally invasive, using methods such as cryolipolysis, ultrasound, radiofrequency, or lasers to reduce fat, tighten skin, and reshape the body without surgical intervention. The popularity of these treatments is growing as more individuals opt for safer, less invasive alternatives to traditional cosmetic surgery. These procedures provide effective fat reduction and skin tightening with less discomfort, reduced risk, and little to no recovery time. Deoxycholic acid obesity drugs contribute to non-surgical body contouring by targeting and breaking down fat cells when injected into specific areas, resulting in the reduction of persistent fat deposits and improved body appearance without the need for surgery. For instance, in June 2024, the International Society of Aesthetic Plastic Surgery, a professional organization based in the United States, reported that in 2023, botulinum toxin remained the most commonly performed non-surgical procedure across all age groups and genders, with eight point eight million treatments performed globally, while hyaluronic acid procedures increased by twenty-nine percent, reaching five point five million treatments. Therefore, the rising demand for non-surgical body contouring is contributing to the growth of the deoxycholic acid obesity drug market.

Leading companies in the deoxycholic acid obesity drug market are focusing on the development of advanced injectable solutions to enhance fat reduction outcomes and improve patient satisfaction. These injectable treatments use deoxycholic acid, a compound that dissolves fat cells, and are administered directly into targeted areas to achieve localized fat reduction. For instance, in March 2024, LG Chem Ltd., a chemicals company based in South Korea, launched Bellacholine for the treatment of submental fat. This non-surgical injection is designed to reduce moderate to severe fat under the chin by safely breaking down fat cells using deoxycholic acid. It features benefits such as a pH level compatible with the body, minimal sediment formation, and the ability to enhance skin elasticity through the stimulation of collagen production.

Major players in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A.

North America was the largest region in the deoxycholic acid obesity drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in deoxycholic acid obesity drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the deoxycholic acid obesity drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Deoxycholic acid obesity drugs are pharmaceutical products containing deoxycholic acid, a naturally occurring bile acid, designed to break down and eliminate localized fat deposits. They are primarily used in non-surgical fat reduction procedures, targeting areas such as the chin, abdomen, and other resistant fat regions.

The primary types of deoxycholic acid obesity drugs include ATX-101 (deoxycholic acid injection, also known as Kybella or Belkyra), experimental or compounded deoxycholic acid formulations, combination therapies, and oral deoxycholic acid products. ATX-101 refers to the commercially approved injectable formulations used for targeted fat reduction. These drugs are available in several forms, including injectable and topical options, and are distributed through channels such as direct sales, retail pharmacies, and online pharmacies. Applications include submental fat reduction, abdominal fat reduction, thighs, arms, flanks, lipomas, localized fat, and cellulite management. Key end-users include aesthetic clinics, dermatology clinics, plastic surgery centers, hospitals, and medical administration facilities.

The deoxycholic acid obesity drugs market research report is one of a series of new reports that provides deoxycholic acid obesity drugs market statistics, including deoxycholic acid obesity drugs industry global market size, regional shares, competitors with a deoxycholic acid obesity drugs market share, detailed deoxycholic acid obesity drugs market segments, market trends and opportunities, and any further data you may need to thrive in the deoxycholic acid obesity drugs industry. This deoxycholic acid obesity drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The deoxycholic acid obesity drugs market consists of sales of injection lipolysis with bile acid derivatives, investigational and preclinical agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.